S Mielke
Overview
Explore the profile of S Mielke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Savani B, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K
Bone Marrow Transplant
. 2009 Oct;
44(12):769-77.
PMID: 19855439
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive...
12.
Savani B, Mielke S, Adams S, Uribe M, Rezvani K, Yong A, et al.
Leukemia
. 2007 Aug;
21(10):2145-52.
PMID: 17673900
Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell...
13.
Smith N, Marsh S, Scott-Horton T, Hamada A, Mielke S, Mross K, et al.
Clin Pharmacol Ther
. 2006 Dec;
81(1):76-82.
PMID: 17186002
To explore retrospectively the relationships between paclitaxel pharmacokinetics and three known, non-synonymous single-nucleotide polymorphisms (SNPs) in SLCO1B3, the gene encoding organic anion transporting polypeptide (OATP)1B3. Accumulation of [(3)H]paclitaxel was studied...
14.
Mielke S, Solomon S, Barrett A
Cytotherapy
. 2005 Jul;
7(2):109-15.
PMID: 16040390
Despite improved prophylaxis and treatment, GvHD remains a major limitation to optimal allogeneic stem cell transplantation. Ex vivo selective depletion (SD) is a strategy to prevent GvHD, in which host-reactive...
15.
Mross K, Haring B, Hollander N, Mielke S, Behringer D, Massing U, et al.
Onkologie
. 2003 Feb;
25(6):503-8.
PMID: 12566894
Purpose: Aim of this study was to characterize the difference in pharmacokinetics (PK) of paclitaxel (PAC) after 1-h and 3-h infusion in humans and to define a pharmacodynamic relationship between...
16.
Jakob M, Mielke S, Keller H, Metzger U
Handchir Mikrochir Plast Chir
. 1999 Sep;
31(4):241-5; discussion 246-7.
PMID: 10481799
Background: In the clinical routine of our City Hospital Triemli, Zürich, Switzerland, we prefer to treat old patients with fractures of the distal radius conservatively. It was our aim to...
17.
Mielke S, Meden H, Kuhn W
Med Hypotheses
. 1998 Jul;
50(5):359-62.
PMID: 9681912
Although oncogenes are involved in tumor development and progression, their activation during human ontogenesis is inseparably associated with normal fetal development. The c-erbB-2-encoded oncoprotein p185 (HER-2/neu) is overexpressed on fetal...
18.
Mielke S, Meden H, Marx D, Wuttke W, Kuhn W
Gynecol Endocrinol
. 1997 Aug;
11(4):237-41.
PMID: 9272419
The c-erbB-2-encoded oncoprotein p185 (HER2) is overexpressed in the fetal epithelium, the placenta and several carcinomas. Elevated serum levels of the released ectodomain (p105) were found in cancer patients and...
19.
Mielke S, Meden H, RAAB T, Wuttke W, Kuhn W
Anticancer Res
. 1997 Jul;
17(4B):3125-7.
PMID: 9329617
Background: The 105 kDa extracellular domain of c-erbB-2 encoded protein p185 is detectable in serum. Elevated p105 serum levels were found in patients with breast and ovarian cancer and in...
20.
Meden H, Mielke S, Marx D, Wuttke W, Kuhn W
Anticancer Res
. 1997 Jul;
17(4B):3075-7.
PMID: 9329605
Background: In breast and ovarian cancer patients elevated serum levels of the oncoprotein p105 were detected. We examined the influence of endocrine factors on the p105 serum concentration. Materials And...